Celgene and BMS-backed cancer therapy developer Repare Therapeutics has filed to go public after raising more than $165m in equity financing.
Canada-based precision oncology drug developer Repare Therapeutics has filed for an initial public offering days after securing $15m from pharmaceutical firm Bristol Myers Squibb (BMS) through a research collaboration agreement.
Repare has filed to raise up to $100m in the offering, which is slated to take place on the Nasdaq Global Market. Its investors also include Celgene Switzerland, an affiliate of pharmaceutical company Celgene.
Founded in 2016, Repare is working on therapeutics targeted at cancer patients in genetically defined…
